Indications and uses
cures most jock itch (tinea cruris) relieves itching, burning, cracking, and scaling which accompany this condition
cures most jock itch (tinea cruris) relieves itching, burning, cracking, and scaling which accompany this condition
adults and children 12 years and over wash the affected area with soap and water and dry completely before applying to open remove clear cap. hold can 4" to 6" from skin. Press and hold to spray a thin layer over affected area spray affected area once a day (morning or night) for 1 week or as directed by a doctor release to stop spray wipe excess from spray opening after each use return cap to can wash hands afte...
store at 8° - 25° C (46° - 77° F)
Terbinafine hydrochloride
Antifungal
For external use only
do not get into eyes. If contact occurs, rinse eyes thoroughly with water.
if too much irritation occurs or gets worse.
If swallowed, get medical help or contact a Poison Control
Center right away.
store at 8° - 25° C (46° - 77° F)
Full Prescription Strength
Continuous Spray Action
Cures Most Jock Itch
For Effective Relief of Itching & Burning
Distr. By:
Ethanol, polyoxyl 20 cetostearyl ether, propylene glycol, purified water
call 1-800-452-0051 or visit us at
www.lamisilat.com
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 992536 | LamISIL AT 1 % Topical Spray | PSN | 3 |
| 992535 | terbinafine HCl 1 % Topical Spray | PSN | 3 |
| 992536 | terbinafine hydrochloride 10 MG/ML Topical Spray [Lamisil] | SBD | 3 |
| 992535 | terbinafine hydrochloride 10 MG/ML Topical Spray | SCD | 3 |
| 992536 | Lamisil 1 % Topical Spray | SY | 3 |
| 992536 | Lamisil 10 MG/ML Topical Spray | SY | 3 |
| 992536 | Lamisil AT 1 % Topical Spray | SY | 3 |
| 992535 | terbinafine hydrochloride 1 % Topical Spray | SY | 3 |
| Class | Version | Type | Effective |
|---|---|---|---|
| TERBINAFINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 55a24767-1759-5f6a-8888-ea4aa0adac21 | Product name | 1 | 20140508 |
| db9701af-cb4f-b8ba-d282-6bc5b6b7c467 | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 54868-6105-0 | 2019-09-24 | C162847 | 48780-1 | 9350213a-426b-c013-e053-90daa90a1393 | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 54868-6105-0 | Lamisil | 125 mL in 1 BOTTLE, SPRAY | SPRAY | 125 | 3 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 54868-6105 | LAMISIL (TERBINAFINE HYDROCHLORIDE) SPRAY [PHYSICIANS TOTAL CARE, INC.] | 3 | 1 package rows | 20100809_792eb340-7202-4c06-b488-033ca8a63859.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 54868-6105-0 | ML - Milliliter | 54868-6105 | 61d21a93-8c86-4fca-89ce-3d8942a030ce | 1 | 2012-07-24 |
| 0067-6293-83 | ML - Milliliter | 0067-6293 | 1eafdc82-7dfa-4915-9f4e-3c381bebeede | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| TERBINAFINE HYDROCHLORIDE | ACTIVE INGREDIENT | 012C11ZU6G | 3 | |
| TERBINAFINE | ACTIVE MOIETY | G7RIW8S0XP | 3 | |
| ALCOHOL | INACTIVE INGREDIENT | 3K9958V90M | 3 | |
| POLYOXYL 20 CETOSTEARYL ETHER | INACTIVE INGREDIENT | YRC528SWUY | 3 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 3 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 54868-6105 | 54868-6105-0 |
| 0067-6293 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| TERBINAFINE HYDROCHLORIDE | 012C11ZU6G | ACTIB |
| ALCOHOL | 3K9958V90M | IACT |
| POLYOXYL 20 CETOSTEARYL ETHER | YRC528SWUY | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| WATER | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SYSTEM / TOPICAL | 4200 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / INTRAMUSCULAR | 4000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SUSPENSION / RECTAL | 0.35 %v/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SHAMPOO / TOPICAL | 714 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / INTRAMUSCULAR | 400 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT, AUGMENTED / TOPICAL | 714 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPONGE / TOPICAL | 40 %w/w | ||
| POLYOXYL 20 CETOSTEARYL ETHER | POLYOXYL 20 CETOSTEARYL ETHER | YRC528SWUY | GEL / TOPICAL | 2 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / RECTAL | 90400 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CONCENTRATE / ORAL | 7000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, METERED / RESPIRATORY (INHALATION) | 26664 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / OPHTHALMIC | 0.6 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / NASAL | 5 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / RESPIRATORY (INHALATION) | 5 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, FOAM / TOPICAL | 4504 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / ORAL | 3563 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CONCENTRATE / ORAL | 198 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / INTRAMUSCULAR | 1491 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / INTRAVENOUS | 99 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, METERED / RECTAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / TOPICAL | 5148 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / SUBLINGUAL | 36 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL, METERED / TOPICAL | 1225 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | DROPS / ORAL | 210 mg/1ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SYRUP / ORAL | 5700 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SHAMPOO, SUSPENSION / TOPICAL | 2 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / INTRAVENOUS | 16624 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / TOPICAL | 9971 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CREAM, AUGMENTED / TOPICAL | 8 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, SPRAY / TOPICAL | 561 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / TOPICAL | 3633 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CAPSULE / ORAL | 882 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SUSPENSION / ORAL | 681 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / OPHTHALMIC | 1 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / TRANSDERMAL | 49.37 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION, CONCENTRATE / INTRAVENOUS | 4000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / SUBCUTANEOUS | 149 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | JELLY / TOPICAL | 20 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED / ORAL | 96 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, EXTENDED RELEASE / ORAL | 8 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 19 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUPPOSITORY / VAGINAL | 252 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / TRANSDERMAL | 90 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, METERED / NASAL | 70 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION, EXTENDED RELEASE / ORAL | 1000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / RECTAL | 898 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / RECTAL | 3315 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, DELAYED RELEASE / ORAL | 36 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / VAGINAL | 6.4 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TAMPON / VAGINAL | 62.1 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / TOPICAL | 4522 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / SUBLINGUAL | 397 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL, METERED / TRANSDERMAL | 3675 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / INTRAVENOUS | 400 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CREAM / TOPICAL | 76000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION, EMULSION / INTRAVENOUS | 520 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL / TOPICAL | 19.2 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / RESPIRATORY (INHALATION) | 0.08 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / AURICULAR (OTIC) | 10 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION, CONCENTRATE / INTRAVENOUS | 50.33 %w/v |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021124-001 | LAMISIL AT | TERBINAFINE HYDROCHLORIDE | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | |
| N021124-002 | LAMISIL AT | TERBINAFINE HYDROCHLORIDE | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021124-001 | LAMISIL AT | 1% | SOLUTION / TOPICAL | RLD, RS | 2000-03-17 | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021124-002 | LAMISIL AT | 1% | SPRAY / TOPICAL | RLD, RS | 2000-03-17 | 74a2ff9319b5… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| db793c72-3826-4b5c-a32a-952cd3d85cd9 | 792eb340-7202-4c06-b488-033ca8a63859 | 2010-01-01 | Warnings | db793c72-3826-4b5c-a32a-952cd3d85cd9 792eb340-7202-4c06-b488-033ca8a63859 |
Adverse event summaries are temporarily unavailable. Other product information remains available.